Use of aristoloxazine c having anticancer activity

Patent metadata

Field	Value
Publication number	US-2025059203-A1
Application number	US-202218723290-A
Country	US
Kind code	A1
Filing date	Dec 21, 2022
Priority date	Dec 21, 2021
Publication date	Feb 20, 2025
Grant date	—

Abstract

The present invention relates to an anticancer use of aristoloxazine C, and more specifically to a pharmaceutical composition and a health functional food composition which use aristoloxazine C represented by Chemical Formula 1 or an isomer or pharmaceutically acceptable salt thereof, a method for preventing, ameliorating or treating cancer by using same; and a method for isolating aristoloxazine C.

First claim

1 - 8 . (canceled)

9 . A method for isolating aristoloxazine C represented by Chemical Formula 1 from Asarum heterotropoides roots, comprising the steps of:

(a) extracting Asarum heterotropoides roots with an ethanol solvent to obtain an ethanol extract of the Asarum heterotropoides roots;
(b) obtaining an ethyl acetate fraction by systematically fractionating the ethanol extract of the Asarum heterotropoides roots in the order of hexane, ethyl acetate and water;
(c) performing flash chromatography on the ethyl acetate fraction by using a water-methanol mixture as an effluent solvent to obtain a fraction; and
(d) purifying the aristoloxazine C by subjecting the fraction obtained after performing column chromatography to semi-preparative chromatography by using a water-acetonitrile mixture as an effluent solvent.

10 . The method of claim 9 , wherein the ethanol solvent in step (a) is 50 to 90% ethanol.

11 . The method of claim 9 , wherein the water-methanol mixture in step (c) is applied at a concentration gradient of 6:4 to 1:9.

12 . The method of claim 9 , wherein the water-acetonitrile mixture in step (d) is applied at a concentration gradient of 6.5:3.5 to 5.5:4.5.

13 . A method for preventing, ameliorating or treating cancer, comprising the step of administering aristoloxazine C represented by Chemical Formula 1, an isomer or a pharmaceutically acceptable salt thereof to a subject in need thereof:

14 . The method of claim 13 , wherein the isomer includes a racemate, an enantiomer, a diastereomer, a mixture of enantiomers or a mixture of diastereomers.

15 . The method of claim 13 , wherein the aristoloxazine C is isolated from Asarum heterotropoides roots.

16 . The method of claim 13 , wherein the aristoloxazine C, isomer or pharmaceutically acceptable salt thereof exhibits an effect of inhibiting cancer cells or inhibiting or delaying tumor development.

17 - 20 . (canceled)

Assignees

• Korea Inst Oriental Medicine

Inventors

• Lee Jun
• Seo Young Hye
• Moon Byeong Cheol
• Lee A Yeong
• Ryu Seung Mok
• Kim Hyo Seon

Classifications

• A61K2236/39

  Complex extraction schemes, e.g. fractionation or repeated extraction steps · CPC title

• A61K2236/333

  using mixed solvents, e.g. 70% EtOH · CPC title

• A61K2121/00

  Preparations for use in therapy · CPC title

• A61K36/268

  Asarum (wild ginger) · CPC title

• A61K31/536

  ortho- or peri-condensed with carbocyclic ring systems · CPC title